PROVEN EFFICACYIN TREATINGNAIL PSORIASIS1*

Sustained improvement in nail psoriasis up to 1 year1,a,b

aESTEEM 1 study. Data as observed; includes patients initially randomized to OTEZLA 30 mg BID or placebo at week 0 who were PASI-75 responders at week 32 and continued to receive OTEZLA through week 52

OTEZLA IMPROVESNAIL PSORIASIS2,3

Sustained improvement in NAPSI score2,3,a

aLIBERATE study. Includes patients with NAPSI score ≥1 at baseline with a baseline value and a post-baseline value at the study week. Missing scores were imputed using the LOCF methodology. Mean NAPSI score at baseline was 4.14 (placebo) and 4.18 (OTEZLA).

References:

Reich K, Goodfield, M, Green L, et al. Efficacy and safety of apremilast through 104 weeks in subjects with moderate to severe psoriasis randomized to placebo, apremilast, or etanercept who continued on or switched to apremilast after week 16 on a phase 3b study. Presented at: the 2017 ACR/ARHP Annual Meeting: November 3-8, 2017; San Diego, CA.

Psoriatic Arthritis

Disclaimer: This is an international website for OTEZLA® (apremilast). The information on this site is not country-specific. It may contain information that is outside the approved indications in the country in which you are located. If you are a US resident, please click on the US residents link at the top of this page.